Observed and projected DFS and OS for upfront vs delayed HSCT for patients with intermediate-risk AML. (A) DFS curves for upfront and delayed HSCT. These Kaplan-Meier curves compare the DFS of patients with intermediate-risk AML treated with upfront HSCT vs delayed HSCT over a follow-up period of 48 months. The blue line represents DFS for the delayed HSCT group, while the red line represents DFS for the HSCT group. (B) OS curves for upfront and delayed HSCT. These Kaplan-Meier curves show the OS of patients with intermediate-risk AML treated with upfront HSCT vs delayed HSCT over a follow-up period of 48 months. The blue line corresponds to the delayed HSCT arm, and the red line represents the HSCT group. (C) PSA of DFS beyond 48 months. This PSA model extends DFS projections up to 624 months (∼52 years), comparing outcomes for delayed HSCT (blue) and upfront HSCT (red). The dashed vertical lines mark significant time points at 48 months (transition from observed to modeled data), and the extrapolated end point at 624 months. This figure predicts long-term DFS trends based on survival probabilities. (D) PSA of OS beyond 48 months. This PSA model extrapolates OS projections for delayed HSCT (blue) and upfront HSCT (red) up to 624 months. As in panel C, dashed vertical lines denote the 48-month cutoff between observed and modeled data, along with the extrapolated end point at 624 months. This analysis provides insight into the potential long-term survival benefits of each treatment.
Figure 1.

Observed and projected DFS and OS for upfront vs delayed HSCT for patients with intermediate-risk AML. (A) DFS curves for upfront and delayed HSCT. These Kaplan-Meier curves compare the DFS of patients with intermediate-risk AML treated with upfront HSCT vs delayed HSCT over a follow-up period of 48 months. The blue line represents DFS for the delayed HSCT group, while the red line represents DFS for the HSCT group. (B) OS curves for upfront and delayed HSCT. These Kaplan-Meier curves show the OS of patients with intermediate-risk AML treated with upfront HSCT vs delayed HSCT over a follow-up period of 48 months. The blue line corresponds to the delayed HSCT arm, and the red line represents the HSCT group. (C) PSA of DFS beyond 48 months. This PSA model extends DFS projections up to 624 months (∼52 years), comparing outcomes for delayed HSCT (blue) and upfront HSCT (red). The dashed vertical lines mark significant time points at 48 months (transition from observed to modeled data), and the extrapolated end point at 624 months. This figure predicts long-term DFS trends based on survival probabilities. (D) PSA of OS beyond 48 months. This PSA model extrapolates OS projections for delayed HSCT (blue) and upfront HSCT (red) up to 624 months. As in panel C, dashed vertical lines denote the 48-month cutoff between observed and modeled data, along with the extrapolated end point at 624 months. This analysis provides insight into the potential long-term survival benefits of each treatment.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal